Enliven Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELVN research report →
Range $70 – $82
Price Chart
About the company
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia.
- CEO
- Richard A. Fair
- IPO
- 2020
- Employees
- 65
- HQ
- Burlingame, CO, US
Get TickerSpark's AI analysis on ELVN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.42B
- P/E
- -27.62
- PEG
- -3.34
- P/S
- 0.00
- P/B
- 4.13
- EV/EBITDA
- -28.79
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -16.91%
- ROIC
- -15.41%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-263,000+0.0%
- Op Income
- $-119,658,000
- Net Income
- $-103,694,000-16.5%
- EPS
- $-1.83+3.2%
- OCF Growth
- +3.9%
- FCF Growth
- +3.8%
- 52W High
- $62.32
- 52W Low
- $14.79
- 50D MA
- $45.50
- 200D MA
- $44.21
- Beta
- 0.24
- RSI (14)
- 50
- Avg Volume
- 1.35M
No earnings-call transcripts are available for ELVN yet.
- Free Float
- 63.8%
- Shares Outstanding
- 73.60M
- Float Shares
- 46.99M
of shares held by institutions
222 13F filers
Buy/sell ratio 0.64. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 10.83M | ▲ 802.71K |
| Orbimed Advisors LLC | 6.78M | 0 |
| Polar Capital Holdings PLC | 6.43M | ▼ 5.37K |
| Blackrock, Inc. | 5.71M | ▲ 1.35M |
| Commodore Capital LP | 3.27M | 0 |
| Vestal Point Capital, LP | 3.23M | ▼ 775.00K |
| Vanguard Capital Management LLC | 2.89M | ▲ 324.11K |
| Vanguard Group Inc | 2.80M | ▲ 248.65K |
| Price T Rowe Associates Inc | 2.35M | ▼ 553.70K |
| Fairmount Funds Management LLC | 1.86M | 0 |
| Geode Capital Management, LLC | 1.71M | ▲ 301.72K |
| State Street Corp | 1.55M | ▲ 333.15K |
Held by 316 ETFs
Biggest fund positions in ELVN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Collins Helen Louise | other | 5,000 |
| Nov 17, 26 | Collins Helen Louise | other | 5,000 |
| Nov 17, 26 | Collins Helen Louise | sell | 4,939 |
| Nov 17, 26 | Collins Helen Louise | sell | 61 |
| Oct 30, 26 | Kunkel Lori Anne | other | 7,300 |
| Oct 30, 26 | Kunkel Lori Anne | other | 3,741 |
| Oct 30, 26 | Kunkel Lori Anne | other | 7,300 |
| Oct 30, 26 | Kunkel Lori Anne | other | 3,741 |
| Oct 19, 26 | Hohl Benjamin | other | 6,018 |
| Oct 19, 26 | Hohl Benjamin | other | 6,018 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ELVN coverage
Recent articles, reports, and earnings notes.
No research on ELVN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ELVN report →Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
prnewswire.com · Nov 5
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
prnewswire.com · Oct 14
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
prnewswire.com · Oct 6
Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling
defenseworld.net · Oct 6
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
benzinga.com · Oct 2
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Enliven Therapeutics to Present at Upcoming Investor Conferences
prnewswire.com · Sep 3
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing
seekingalpha.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.